» Articles » PMID: 4310172

Further Observations on the Inhibitory Effect of Myxoviruses on a Transplantable Murine Leukemia

Overview
Date 1969 Oct 1
PMID 4310172
Citations 7
Authors
Affiliations
Soon will be listed here.
Citing Articles

Trial watch: TLR3 agonists in cancer therapy.

Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E Oncoimmunology. 2020; 9(1):1771143.

PMID: 32934877 PMC: 7466857. DOI: 10.1080/2162402X.2020.1771143.


Antibody mediated complement dependent lysis of virus infected cells.

Oldstone M, Lampert P Springer Semin Immunopathol. 2020; 2(3):261-283.

PMID: 32214619 PMC: 7087522. DOI: 10.1007/BF00198720.


Recent advances of oncolytic virus in cancer therapy.

Mondal M, Guo J, He P, Zhou D Hum Vaccin Immunother. 2020; 16(10):2389-2402.

PMID: 32078405 PMC: 7644205. DOI: 10.1080/21645515.2020.1723363.


Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Zamarin D, Palese P Future Microbiol. 2012; 7(3):347-67.

PMID: 22393889 PMC: 4241685. DOI: 10.2217/fmb.12.4.


Complement-dependent antiviral monospecific antibody-mediated lysis of murine cells coated with Sendai virus or its envelope component.

Hosaka Y, Fukami Y, Yasuda Y, Bonilla J Infect Immun. 1980; 27(2):355-63.

PMID: 6247274 PMC: 550772. DOI: 10.1128/iai.27.2.355-363.1980.